ImmunityBio (IBRX) Cash & Equivalents Growth (5y) (2019 - 2026)

ImmunityBio (IBRX) Cash & Equivalents Growth (5y) (2019 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 ImmunityBio 7.22 Bn 6.84 Bn 43.97 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 35.65%
Dec 31, 2025 20.40%
Sep 30, 2025 -6.58%
Jun 30, 2025 3.63%
Mar 31, 2025 0.67%
Dec 31, 2024 13.60%
Sep 30, 2024 43.67%
Jun 30, 2024 49.75%
Mar 31, 2024 42.96%
Dec 31, 2023 73.63%
Sep 30, 2023 63.33%
Jun 30, 2023 200.01%
Mar 31, 2023 245.78%
Dec 31, 2022 34.39%
Sep 30, 2022 45.23%
Jun 30, 2022 9.66%
Mar 31, 2022 21.76%
Dec 31, 2021 86.24%
Sep 30, 2021 15.49%
Jun 30, 2021 17.04%